13:33 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Santhera's congenital muscular dystrophy candidate well tolerated in Phase I

Santhera Pharmaceuticals Holding AG (SIX:SANN) reported data from the Phase I CALLISTO trial in 20 ambulatory and non-ambulatory patients ages 5-16 with congenital muscular dystrophy showing that once-daily 0.02-0.08 mg/kg doses of oral omigapil (SNT-317,...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Santhera musculoskeletal news

Santhera received a $246,000 grant from FDA under its Orphan Products Grants Program to support the ongoing open-label, dose-escalation, U.S. Phase I CALLISTO trial evaluating omigapil in ambulatory and non-ambulatory patients with congenital muscular dystrophy....
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Omigapil: Completed Phase I enrollment

Santhera completed enrollment of 20 ambulatory and non-ambulatory patients ages 5-16 in the open-label, dose-escalation, U.S. Phase I CALLISTO trial evaluating 0.02, 0.08 and 0.2 mg/kg/day oral omigapil for 12 weeks. In 2007, the company...
08:00 , Jan 28, 2013 |  BC Week In Review  |  Company News

Callisto, Synergy Pharmaceuticals deal

Synergy completed its acquisition of principal stockholder Callisto in a stock deal. The deal values Callisto at $185.1 million based on Synergy's close of $6.47 on Jan. 17, before the deal closed. Each Callisto common...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

Plecanatide: Completed Phase IIb/III enrollment

Synergy completed enrollment of about 880 patients in a double-blind, placebo-controlled, U.S. Phase IIb/III trial (SP304-20210) evaluating 0.3, 1 or 3 mg oral plecanatide once daily for 12 weeks. In July, Synergy said it will...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Company News

Callisto, Synergy deal

Synergy will acquire its principal stockholder Callisto in a stock deal. The deal values Callisto at $117 million based on Synergy's close of $4.34 on July 20, before the deal was announced. Each Callisto common...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Company News

Callisto, Ironwood, Synergy Pharmaceuticals gastrointestinal news

Synergy said that the opposition division of the European Patent Office upheld its patent covering plecanatide in a December oral hearing. In April 2010, European Patent No. 1,379,224 was granted to Synergy, which Ironwood opposed...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

Callisto, Ironwood gastrointestinal news

Synergy Pharmaceuticals Inc. (OTCQB:SGYPD, New York, N.Y.), which is majority owned by Callisto, filed a suit in the N.Y. State Supreme Court against Ironwood and its SVP of R&D and Chief Scientific Officer Mark Currie....
07:00 , Oct 31, 2011 |  BC Week In Review  |  Clinical News

Plecanatide: Phase II/III started

Synergy Pharmaceuticals Inc. (OTCQB:SGYP, New York, N.Y.) began a double-blind, placebo-controlled, U.S. Phase II/III trial (SP304-20210) to evaluate 0.3, 1 or 3 mg oral plecanatide once daily for 12 weeks in 880 patients. Synergy is...
08:00 , Jan 10, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biotie Therapies Corp. (HSE:BTH1V) gained €0.18 (36%) to €0.68 on Monday after partner H. Lundbeck A/S (CSE:LUN) said it plans to submit an MAA next half for nalmefene to treat alcohol addiction. Biotie...